The Study
Autoantibodies to the TSH Receptor—from discovery to understanding the mechanisms of action and to new therapeutics
This article is like a storybook that tells you how scientists figured out over many years that certain body proteins cause a thyroid disease. It doesn't test anything new—it just explains what others have already discovered. So we can't say for sure that a new medicine will work for everyone just because this article talks about it.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
In Graves' disease, the body makes antibodies that trick the thyroid into making too much hormone. Scientists found one antibody (K1-70TM) that acts like a lock, blocking those bad antibodies and stopping the thyroid from overproducing.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this could mean a new targeted treatment that avoids damaging the thyroid or using lifelong drugs.
- 2K1-70TM reduced eye swelling and improved symptoms in one patient; in trials, a single dose lowered thyroid hormone levels for weeks.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Related Content
Claims (6)
Graves' disease is a condition where the immune system produces antibodies that bind to the thyroid gland and cause it to produce too much thyroid hormone.
The antibody K1-70TM attaches to the thyroid-stimulating hormone receptor and prevents both thyroid-stimulating hormone and harmful autoantibodies from activating it, leading to lower thyroid hormone levels and reduced eye inflammation in Graves' ophthalmopathy in one patient and an early clinical trial.
In Graves' disease, antibodies that bind to the thyroid-stimulating hormone receptor either continuously activate it, resulting in excessive thyroid hormone production and hyperthyroidism, or block its activation, resulting in reduced thyroid hormone production and hypothyroidism. Both types of antibodies can be present in the same individual at the same time or at different times.
Specific changes to the thyroid-stimulating hormone receptor's outer structure allow scientists to isolate it and use it in medical tests and treatments such as antibody-based diagnostics and CAR-T cell therapies.
A laboratory-made antibody called M22TM, originally isolated from a person with Graves’ disease, binds tightly to the TSH receptor and is used in diagnostic tests worldwide to detect thyroid-stimulating autoantibodies.
Cryo-electron microscopy images show that two types of antibodies targeting the TSH receptor attach to different parts of the receptor: one type holds it in an active state, and the other type blocks hormone binding without changing the receptor's baseline activity.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.